查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1925399

客製化基因合成​​服務市場：按應用、最終用戶、技術、基因長度和服務速度分類——2026-2032年全球預測

Custom Gene Synthesis Service Market by Application, End User, Technology, Gene Length, Service Speed - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，客製化基因合成​​服務市場價值將達到 12.8 億美元，到 2026 年將成長至 14.7 億美元，到 2032 年將達到 34.8 億美元，複合年成長率為 15.31%。

關鍵市場統計數據
基準年 2025 12.8億美元
預計年份：2026年 14.7億美元
預測年份 2032 34.8億美元
複合年成長率 (%) 15.31%

策略定向、品質促進因素與採購考量：客製化基因合成​​服務如何塑造現代生物技術專案執行

本執行摘要全面概述了現代客製化基因合成​​服務及其在生物技術研發、治療藥物開發、工業生物催化、農業應用和診斷等領域的戰略作用。重點闡述了核心競爭力、差異化技術方法，以及合成服務提供者如何在從概念到檢驗候選產品的整個創新流程中創造價值。影響採購決策和合作夥伴選擇的關鍵因素包括對服務彈性、合成保真度和下游檢驗服務整合的重視程度。

新興合成技術和不斷演進的服務模式如何重塑生物技術領域的供應商差異化、客戶期望和策略夥伴關係

客製化基因合成​​領域正經歷著變革性的轉變，這主要得益於技術的普及化、對客製化基因構建體日益成長的需求，以及供應商與終端用戶之間夥伴關係的不斷深化。酶促合成和微流體控合成方法的進步降低了複雜序列的進入門檻，同時提高了準確性和環境永續性。同時，將設計協助、序列檢驗和下游交貨選項整合在一起的模組化服務模式，正在重新定義客戶的期望，並促進從一次性訂單向長期合作關係的轉變。

評估美國關稅到 2025 年的營運和策略影響，以及它們對採購方式、前置作業時間和成本可預測性的重組影響。

美國關稅的累積影響將持續到2025年，為基因合成供應商及其客戶帶來了一系列營運和策略的考量。試劑、專用設備和某些耗材的關稅正在擠壓供應商的利潤空間，並加劇國際供應鏈的摩擦，促使各方重新評估籌資策略。許多供應商和終端用戶正在透過多元化採購管道、增加關鍵材料的儲備庫存以及尋找替代試劑供應商來應對，從而降低對單一供應來源的依賴風險。

按應用程式、最終用戶、技術、基因長度和服務速度進行詳細的細分分析，以使提供者的能力與客戶價值提案相符。

細分分析揭示了需求促進因素和服務期望的細微差別，這些差別因應用、最終用戶、技術、基因長度和服務速度而異。在應用領域內，農業生物技術、診斷開發、工業生物催化、研發和治療開發有著各自獨特的需求。工業生物催化進一步細分為生質燃料生產和聚合物合成，而治療開發則細分為抗體工程、基因治療和疫苗開發。這些應用層面的差異決定了對規模、序列複雜性和檢驗嚴謹性的要求。在最終用戶方面，學術和政府研究機構、生技公司、受託研究機構和製藥公司的採用趨勢各不相同，它們各自優先考慮的因素組合也不同，例如成本敏感度、法規遵循和夥伴關係深度。

區域趨勢和策略採購模式正在影響美洲、歐洲、中東和非洲以及亞太地區的供應商選擇和物流。

區域趨勢對採購行為、監管預期和供應商網路結構有顯著影響。在美洲，生物技術中心、大規模製藥研發中心以及實力雄厚的風險投資支持的Start-Ups高度集中，推動了市場需求，這些企業優先考慮快速交付和一體化服務。美洲地區對本土製造能力和品質基礎設施的投資，使得能夠提供快速交貨和強大智慧財產權保護的供應商更受青睞。歐洲、中東和非洲地區（EMEA）的特點是管理體制多樣化，集中式製造能力也存在差異，客戶往往更傾向於那些具備監管專業知識、本地化品管和靈活物流解決方案的供應商。

成熟供應商、專業創新者和整合商之間的競爭動態和差異化能力正在重塑服務組合和打入市場策略。

在公司層面，市場根據技術服務的能力、規模和深度進行分層。成熟的供應商利用其廣泛的技術組合、經認證的品質系統和深厚的監管經驗，為複雜的治療和診斷領域的客戶提供服務。同時，專業供應商則透過專注於狹窄的高價值應用或投資專有的合成化學技術和自動化來脫穎而出。新興的Start-Ups和利基企業正透過採用酶工作流程、微流體整合和平台級改進來加速創新，從而縮短週期時間並提高序列準確性。受託研究機構(CRO) 作為整合者發揮關鍵作用，提供將合成與下游表徵和功能測試相結合的配套服務，深受尋求單一供應商責任制的製藥客戶的青睞。

切實可行的策略舉措，幫助領導企業提升韌性、加快交付速度並抓住高價值機會。

產業領導者應優先採取一系列切實可行的行動，將現有能力轉化為永續的優勢。首先，投資於自動化和平台互通性，以縮短週期時間，並實現對各種片段長度的可預測、擴充性的交付。同時，也應增加對品質保證的投入，包括正交檢驗和強大的可追溯性系統，以滿足治療和診斷客戶的嚴格要求。其次，實現供應商和試劑來源多元化，以降低關稅風險和供應鏈脆弱性，並評估近岸外包和區域夥伴關係作為應對跨境貿易波動的策略性緩解措施。第三，制定差異化的服務層級，將快速交貨服務與檢驗的績效指標明確掛鉤，從而在維持標準工作流程吞吐量的同時，為時間敏感型專案提供溢價。

研究採用嚴謹的混合方法研究途徑，結合了初次訪談、技術檢驗、文件分析和多方相關人員檢驗，從而得出可靠的研究結果。

本分析的調查方法結合了定性和定量資訊來源，建構了一個穩健的、三角驗證的客製化基因合成​​現狀圖景。主要工作包括對學術機構、生物技術公司、受託研究機構(CRO) 和製藥公司的管理人員、技術總監和採購決策者進行深度訪談，以了解實際的採購標準、品質期望和服務挑戰。此外，還與專家進行了技術諮詢，以檢驗晶片合成、柱式合成、酶法合成和微流體合成等技術方法之間的差異，從而確保性能屬性的準確呈現。

最終綜合策略槓桿、區域考量和能力優先事項，供希望將基因合成優勢轉化為專案層面優勢的相關人員參考。

總之，客製化基因合成​​服務在生物技術、工業、農業和診斷應用領域佔據技術能力與計畫成果的策略交會點。那些兼具技術廣度、深厚的品質系統、以客戶為中心的服務層級以及穩健的供應鏈策略的供應商，最有可能贏得高價值合約。到2025年，關稅環境的變化使得供應來源多元化和區域生產力計畫變得更加緊迫，促使買賣雙方重新評估採購模式和合約風險分配。同時，按應用、最終用戶、技術、基因長度和服務速度進行細分，為將供應商優勢與客戶需求相匹配提供了一個切實可行的藍圖，從而能夠做出更精準的採購決策並製定清晰的產品藍圖。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 按應用分類的客製化基因合成​​服務市場

  • 農業生物技術
  • 診斷藥物研發
  • 工業生物催化劑
    • 生質燃料生產
    • 聚合物合成
  • 研究與開發
  • 治療藥物研發
    • 抗體工程
    • 基因治療
    • 疫苗研發

9. 按最終用戶分類的客製化基因合成​​服務市場

  • 學術和政府研究機構
  • 生技公司
  • CRO（受託研究機構）
  • 製藥公司

10. 按技術分類的客製化基因合成​​服務市場

  • 基於晶片的合成
  • 柱層析合成
  • 酵素合成
  • 微流體控合成

11. 依基因長度分類的客製化基因合成​​服務市場

  • 長片段
  • 中型碎片
  • 短片段

12. 依服務速度分類的客製化基因合成​​服務市場

  • 表達
  • 快速交貨
  • 標準

13. 各地區客製化基因合成​​服務市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 按群體分類的客製化基因合成​​服務市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 各國客製化基因合成​​服務市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

16. 美國客製化基因合成​​服務市場

17. 中國客製化基因合成​​服務市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Ansa Biotechnologies Inc.
  • ATUM
  • Azenta Life Sciences
  • Bio Basic Inc.
  • Bio-Synthesis Inc.
  • Bioneer Corporation
  • DNA Script
  • Eurofins Genomics
  • Evonetix Ltd
  • GenScript Biotech Corporation
  • Integrated DNA Technologies Inc.
  • Merck KGaA
  • OriGene Technologies Inc.
  • ProteoGenix
  • Synbio Technologies LLC
  • Telesis Bio Inc.
  • Thermo Fisher Scientific Inc.
  • Twist Bioscience Corporation
Product Code: MRR-7A380DA7C5EF

The Custom Gene Synthesis Service Market was valued at USD 1.28 billion in 2025 and is projected to grow to USD 1.47 billion in 2026, with a CAGR of 15.31%, reaching USD 3.48 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.28 billion
Estimated Year [2026] USD 1.47 billion
Forecast Year [2032] USD 3.48 billion
CAGR (%) 15.31%

A strategic orientation to custom gene synthesis offerings, quality levers, and procurement considerations shaping modern biotech program execution

This executive summary introduces a comprehensive view of contemporary custom gene synthesis service offerings and their strategic role across biotechnology R&D, therapeutic development, industrial biocatalysis, agricultural applications, and diagnostics. The focus is on clarifying core capabilities, differentiating technology approaches, and articulating how synthesis providers create value along the innovation pipeline from concept to validated product candidate. Emphasis is placed on service speed, synthesis fidelity, and integration of downstream validation services as principal levers that influence procurement decisions and partner selection.

The narrative also frames the interplay between rapid technological improvement and evolving regulatory expectations, highlighting that customers increasingly evaluate providers not only on price and turnaround, but on quality assurance workflows, intellectual property safeguards, and supply chain resilience. With an eye toward enterprise adoption, the introduction explains common procurement scenarios where synthesized genes drive program timelines, enable iterative design cycles, and reduce experimental uncertainty. It closes by situating the subsequent sections as an analytical progression: mapping landscape shifts, assessing tariff influences in 2025, deriving segmentation insights, and offering recommendations designed for leaders who must convert synthesis capability into competitive advantage.

How emergent synthesis technologies and evolving service models are reshaping supplier differentiation, customer expectations, and strategic partnerships across biotech

The landscape for custom gene synthesis is undergoing transformative shifts driven by technological democratization, increased demand for bespoke genetic constructs, and evolving partnerships between providers and end users. Advances in enzymatic and microfluidic synthesis methods are reducing barriers to entry for complex sequences while improving accuracy and environmental sustainability. At the same time, modular service models that bundle design support, sequence verification, and downstream delivery options are redefining customer expectations, encouraging a move from transactional orders toward long-term collaborative relationships.

Concurrently, there is a pronounced shift in customers' procurement criteria: speed tiers have crystallized into distinct service corridors with express and rapid turnaround offerings commanding strategic premium for time-sensitive programs. The growth of antibody engineering, gene therapy, and vaccine development has intensified demand for longer fragment synthesis with rigorous QC standards. In parallel, industrial biocatalyst applications such as biofuel production and polymer synthesis are pushing providers to adapt workflows for high-throughput and cost-efficient manufacturing. These changes are prompting suppliers to invest in automation, robust quality management systems, and expanded technical support capabilities, thereby catalyzing a more service-oriented ecosystem that favors depth of technical expertise and operational scalability.

Assessing the operational and strategic consequences of US tariff measures through 2025 and how they reframe sourcing, lead times, and cost predictability

The cumulative impact of United States tariffs implemented through 2025 has introduced a set of operational and strategic considerations for gene synthesis providers and their customers. Tariffs on reagents, specialized instruments, and certain consumables have compressed supplier margins and added friction to transnational supply chains, prompting reassessments of sourcing strategies. Many providers and end users have responded by diversifying procurement channels, increasing buffer inventories for critical inputs, and qualifying alternative reagent suppliers to mitigate single-source exposure.

Regulatory compliance and customs complexity have translated into longer lead times for some imported goods, encouraging nearshoring and regional sourcing where feasible. In practice, this means companies with multi-jurisdictional footprints are increasingly optimizing where they locate assembly and QC functions to avoid tariff layers while preserving access to skilled labor and infrastructure. For contract research organizations and biotechnology firms that rely on foreign-sourced instrumentation, the tariffs have elevated the importance of contractual clarity around cost escalation and delivery timelines. Ultimately, the tariff environment has accelerated strategic conversations around vertical integration, supplier consolidation, and investment in domestic production capacity to safeguard program continuity and to maintain predictable cost bases under fluctuating trade regimes.

Granular segmentation insights by application, end user, technology, gene length, and service speed to align provider capabilities with customer value propositions

Segmentation analysis reveals nuanced demand drivers and service expectations that vary substantially by application, end user, technology, gene length, and service speed. Based on Application, the market exhibits differentiated needs across Agricultural Biotechnology, Diagnostic Development, Industrial Biocatalysts, Research And Development, and Therapeutic Development, where Industrial Biocatalysts further splits into Biofuel Production and Polymer Synthesis and Therapeutic Development further divides into Antibody Engineering, Gene Therapy, and Vaccine Development; these application-level distinctions shape requirements for scale, sequence complexity, and validation rigor. Based on End User, adoption dynamics diverge among Academic And Government Research Institutes, Biotechnology Companies, Contract Research Organizations, and Pharmaceutical Companies, each of which prioritizes different combinations of cost sensitivity, regulatory compliance, and partnership depth.

Based on Technology, the competitive landscape is segmented into Chip Based Synthesis, Column Based Synthesis, Enzymatic Synthesis, and Microfluidic Synthesis, with each technology offering trade-offs in throughput, error profile, and suitability for varying fragment lengths. Based on Gene Length, service patterns separate into Long Fragment, Medium Fragment, and Short Fragment categories, which in turn influence QC protocols and delivery timelines. Finally, based on Service Speed, customers select among Express, Rapid Turnaround, and Standard options according to project urgency and budget constraints. Taken together, these segmentation axes provide a framework for providers to align technical capabilities with customer value propositions and for buyers to articulate procurement priorities that reflect application-specific risk tolerances and performance thresholds.

Regional dynamics and strategic procurement patterns across the Americas, Europe, Middle East & Africa, and Asia-Pacific shaping supplier selection and logistics

Regional dynamics exert a strong influence on procurement behavior, regulatory expectations, and the structure of supplier networks. In the Americas, demand is often driven by a concentration of biotech hubs, large pharmaceutical research centers, and robust venture-backed startups that prioritize rapid timelines and integrated service offerings. Investment in domestic production capacity and quality infrastructure in the Americas supports preferences for suppliers that can offer tight turnaround windows and strong IP protections. In Europe, Middle East & Africa, the landscape is characterized by diverse regulatory regimes and varying levels of centralized capacity, prompting customers to favor suppliers that demonstrate regulatory expertise, localized quality management, and flexible logistics solutions.

Asia-Pacific presents an expansive and heterogeneous market with a mix of well-established contract manufacturers, academic innovation centers, and rapidly growing biotech clusters. Customers in Asia-Pacific often balance cost sensitivity with accelerating demand for high-complexity constructs, which drives interest in automated synthesis platforms and scalable QC workflows. Across all regions, cross-border collaboration, regulatory harmonization efforts, and regional investments in capacity continue to influence where organizations choose to place orders, how they structure multi-supplier strategies, and the extent to which they pursue localized partnerships to reduce lead times and regulatory friction.

Competitive dynamics and capability differentiation among established providers, specialist innovators, and integrators reshaping service portfolios and go-to-market strategies

Company-level dynamics show a market stratified by capability, scale, and depth of technical services. Established suppliers often leverage broad technology portfolios, certified quality systems, and deep regulatory experience to serve complex therapeutic and diagnostic customers, while specialist providers differentiate by focusing on a narrow set of high-value applications or by investing in proprietary synthesis chemistries and automation. Emerging startups and niche players accelerate innovation by introducing enzymatic workflows, microfluidic integration, and platform-level improvements that reduce cycle times and improve sequence fidelity. Contract research organizations play a pivotal role as integrators, offering bundled services that combine synthesis with downstream characterization and functional testing, which appeals to pharmaceutical customers seeking single-vendor accountability.

Competitive dynamics also reflect different go-to-market approaches: some companies pursue volume and cost leadership by optimizing standard fragment pipelines and high-throughput operations, while others emphasize premium services such as long-fragment synthesis, bespoke sequence design, and concierge-level support. Strategic partnerships and M&A activity have concentrated capabilities in areas like antibody engineering and gene therapy, enabling larger providers to offer end-to-end solutions. Companies that succeed tend to invest in rigorous quality control, transparent traceability, and customer-facing analytics that translate technical performance into measurable program benefits for their clients.

Actionable strategic initiatives for leaders to strengthen resilience, accelerate delivery, and capture high-value opportunities through targeted investments and partnerships

Industry leaders should prioritize a set of pragmatic actions to convert capability into sustainable advantage. First, invest in automation and platform interoperability to reduce cycle times and to enable predictable, scalable delivery across a broader range of fragment lengths. This should be paired with stepped-up quality assurance investments, including orthogonal verification and robust traceability systems, to meet the stringent expectations of therapeutic and diagnostic customers. Second, diversify supplier and reagent sourcing to reduce tariff exposure and supply-chain fragility, while evaluating nearshoring or regional partnerships as strategic mitigants to cross-border trade volatility. Third, develop differentiated service tiers that clearly map express and rapid turnaround offerings to verifiable performance metrics, enabling premium pricing for time-critical programs while preserving throughput for standard workflows.

Additionally, build closer collaborations with end users through co-development programs and technical account management to embed services earlier in client development lifecycles. Expand value-added offerings such as design-for-synthesis consulting, sequence optimization, and regulatory documentation support to deepen customer stickiness. Finally, adopt transparent contracting practices that clarify responsibilities for customs, reagent substitutions, and cost escalation to minimize disputes and to maintain trust in multinational engagements. Taken together, these measures can enhance resilience, sharpen competitive positioning, and improve the ability to capture strategic, high-value engagements across applications and regions.

A rigorous mixed-methods research approach integrating primary interviews, technical validation, document synthesis, and multi-stakeholder triangulation for robust insights

The research methodology for this analysis combined qualitative and quantitative sources to build a robust, triangulated view of the custom gene synthesis landscape. Primary engagement included in-depth interviews with executives, technical leads, and procurement decision-makers across academic institutions, biotechnology companies, contract research organizations, and pharmaceutical firms to surface real-world procurement criteria, quality expectations, and service pain points. These interviews were complemented by technical consultations with subject matter experts to validate technology comparisons across chip based, column based, enzymatic, and microfluidic synthesis approaches, ensuring that performance attributes were accurately represented.

Secondary research involved a systematic review of regulatory guidance, manufacturer technical specifications, trade policy notices, and recent patent literature to capture shifts in product capabilities and trade dynamics through 2025. Data were synthesized using a framework that cross-referenced application needs with technology attributes and regional supply chain factors, while quality control steps included cross-validation with multiple industry stakeholders and iterative peer review by domain experts. This layered approach ensured that conclusions reflect operational realities, technical feasibility, and strategic implications without relying on single-source claims, thereby enhancing confidence in the report's recommendations and insights.

Final synthesis of strategic levers, regional considerations, and capability priorities for stakeholders seeking to convert gene synthesis strengths into program-level advantage

In conclusion, custom gene synthesis services occupy a strategic nexus between technological capability and program-level outcomes across biotech, industrial, agricultural, and diagnostic applications. Providers that combine technological breadth with deep quality systems, customer-centric service tiers, and resilient supply-chain strategies are best positioned to win high-value engagements. The tariff environment through 2025 has added urgency to supply diversification and regional capacity planning, encouraging both buyers and suppliers to reassess sourcing models and contractual risk allocation. Meanwhile, segmentation by application, end user, technology, gene length, and service speed provides a pragmatic blueprint for matching provider strengths to customer needs, enabling more precise procurement decisions and clearer product roadmaps.

Leaders should respond by investing strategically in automation, QC, and partnership models that embed them earlier in customer workflows, while balancing near-term operational optimizations with longer-term capability development. The recommendations and regional perspectives offered here provide a foundation for decision-makers to align investments with program priorities, reduce operational risks, and accelerate the delivery of innovation across the full lifecycle of gene-engineered products.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Custom Gene Synthesis Service Market, by Application

  • 8.1. Agricultural Biotechnology
  • 8.2. Diagnostic Development
  • 8.3. Industrial Biocatalysts
    • 8.3.1. Biofuel Production
    • 8.3.2. Polymer Synthesis
  • 8.4. Research And Development
  • 8.5. Therapeutic Development
    • 8.5.1. Antibody Engineering
    • 8.5.2. Gene Therapy
    • 8.5.3. Vaccine Development

9. Custom Gene Synthesis Service Market, by End User

  • 9.1. Academic And Government Research Institutes
  • 9.2. Biotechnology Companies
  • 9.3. Contract Research Organizations
  • 9.4. Pharmaceutical Companies

10. Custom Gene Synthesis Service Market, by Technology

  • 10.1. Chip Based Synthesis
  • 10.2. Column Based Synthesis
  • 10.3. Enzymatic Synthesis
  • 10.4. Microfluidic Synthesis

11. Custom Gene Synthesis Service Market, by Gene Length

  • 11.1. Long Fragment
  • 11.2. Medium Fragment
  • 11.3. Short Fragment

12. Custom Gene Synthesis Service Market, by Service Speed

  • 12.1. Express
  • 12.2. Rapid Turnaround
  • 12.3. Standard

13. Custom Gene Synthesis Service Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Custom Gene Synthesis Service Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Custom Gene Synthesis Service Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Custom Gene Synthesis Service Market

17. China Custom Gene Synthesis Service Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Ansa Biotechnologies Inc.
  • 18.6. ATUM
  • 18.7. Azenta Life Sciences
  • 18.8. Bio Basic Inc.
  • 18.9. Bio-Synthesis Inc.
  • 18.10. Bioneer Corporation
  • 18.11. DNA Script
  • 18.12. Eurofins Genomics
  • 18.13. Evonetix Ltd
  • 18.14. GenScript Biotech Corporation
  • 18.15. Integrated DNA Technologies Inc.
  • 18.16. Merck KGaA
  • 18.17. OriGene Technologies Inc.
  • 18.18. ProteoGenix
  • 18.19. Synbio Technologies LLC
  • 18.20. Telesis Bio Inc.
  • 18.21. Thermo Fisher Scientific Inc.
  • 18.22. Twist Bioscience Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY GENE LENGTH, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY SERVICE SPEED, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY AGRICULTURAL BIOTECHNOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY AGRICULTURAL BIOTECHNOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY AGRICULTURAL BIOTECHNOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY DIAGNOSTIC DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY DIAGNOSTIC DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY DIAGNOSTIC DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY INDUSTRIAL BIOCATALYSTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY INDUSTRIAL BIOCATALYSTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY INDUSTRIAL BIOCATALYSTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY INDUSTRIAL BIOCATALYSTS, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY BIOFUEL PRODUCTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY BIOFUEL PRODUCTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY BIOFUEL PRODUCTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY POLYMER SYNTHESIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY POLYMER SYNTHESIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY POLYMER SYNTHESIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY RESEARCH AND DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY RESEARCH AND DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY RESEARCH AND DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY THERAPEUTIC DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY THERAPEUTIC DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY THERAPEUTIC DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY THERAPEUTIC DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY ANTIBODY ENGINEERING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY ANTIBODY ENGINEERING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY ANTIBODY ENGINEERING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY VACCINE DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY VACCINE DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY VACCINE DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY CHIP BASED SYNTHESIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY CHIP BASED SYNTHESIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY CHIP BASED SYNTHESIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY COLUMN BASED SYNTHESIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY COLUMN BASED SYNTHESIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY COLUMN BASED SYNTHESIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY ENZYMATIC SYNTHESIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY ENZYMATIC SYNTHESIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY ENZYMATIC SYNTHESIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY MICROFLUIDIC SYNTHESIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY MICROFLUIDIC SYNTHESIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY MICROFLUIDIC SYNTHESIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY GENE LENGTH, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY LONG FRAGMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY LONG FRAGMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY LONG FRAGMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY MEDIUM FRAGMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY MEDIUM FRAGMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY MEDIUM FRAGMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY SHORT FRAGMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY SHORT FRAGMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY SHORT FRAGMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY SERVICE SPEED, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY EXPRESS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY EXPRESS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY EXPRESS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY RAPID TURNAROUND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY RAPID TURNAROUND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY RAPID TURNAROUND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY STANDARD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY STANDARD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY STANDARD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY INDUSTRIAL BIOCATALYSTS, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY THERAPEUTIC DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY GENE LENGTH, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY SERVICE SPEED, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY INDUSTRIAL BIOCATALYSTS, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY THERAPEUTIC DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY GENE LENGTH, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY SERVICE SPEED, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY INDUSTRIAL BIOCATALYSTS, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY THERAPEUTIC DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY GENE LENGTH, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY SERVICE SPEED, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY INDUSTRIAL BIOCATALYSTS, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY THERAPEUTIC DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY GENE LENGTH, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY SERVICE SPEED, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY INDUSTRIAL BIOCATALYSTS, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY THERAPEUTIC DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY GENE LENGTH, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY SERVICE SPEED, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY INDUSTRIAL BIOCATALYSTS, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY THERAPEUTIC DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY GENE LENGTH, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY SERVICE SPEED, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY INDUSTRIAL BIOCATALYSTS, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY THERAPEUTIC DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY GENE LENGTH, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY SERVICE SPEED, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY INDUSTRIAL BIOCATALYSTS, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY THERAPEUTIC DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY GENE LENGTH, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY SERVICE SPEED, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY INDUSTRIAL BIOCATALYSTS, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY THERAPEUTIC DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. ASEAN CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY GENE LENGTH, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY SERVICE SPEED, 2018-2032 (USD MILLION)
  • TABLE 155. GCC CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. GCC CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 157. GCC CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY INDUSTRIAL BIOCATALYSTS, 2018-2032 (USD MILLION)
  • TABLE 158. GCC CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY THERAPEUTIC DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 159. GCC CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. GCC CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 161. GCC CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY GENE LENGTH, 2018-2032 (USD MILLION)
  • TABLE 162. GCC CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY SERVICE SPEED, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPEAN UNION CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY INDUSTRIAL BIOCATALYSTS, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY THERAPEUTIC DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY GENE LENGTH, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY SERVICE SPEED, 2018-2032 (USD MILLION)
  • TABLE 171. BRICS CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. BRICS CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 173. BRICS CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY INDUSTRIAL BIOCATALYSTS, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY THERAPEUTIC DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. BRICS CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY GENE LENGTH, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY SERVICE SPEED, 2018-2032 (USD MILLION)
  • TABLE 179. G7 CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 180. G7 CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 181. G7 CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY INDUSTRIAL BIOCATALYSTS, 2018-2032 (USD MILLION)
  • TABLE 182. G7 CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY THERAPEUTIC DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 183. G7 CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 184. G7 CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 185. G7 CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY GENE LENGTH, 2018-2032 (USD MILLION)
  • TABLE 186. G7 CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY SERVICE SPEED, 2018-2032 (USD MILLION)
  • TABLE 187. NATO CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 188. NATO CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 189. NATO CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY INDUSTRIAL BIOCATALYSTS, 2018-2032 (USD MILLION)
  • TABLE 190. NATO CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY THERAPEUTIC DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 191. NATO CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. NATO CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 193. NATO CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY GENE LENGTH, 2018-2032 (USD MILLION)
  • TABLE 194. NATO CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY SERVICE SPEED, 2018-2032 (USD MILLION)
  • TABLE 195. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. UNITED STATES CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 197. UNITED STATES CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 198. UNITED STATES CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY INDUSTRIAL BIOCATALYSTS, 2018-2032 (USD MILLION)
  • TABLE 199. UNITED STATES CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY THERAPEUTIC DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 200. UNITED STATES CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 201. UNITED STATES CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY GENE LENGTH, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY SERVICE SPEED, 2018-2032 (USD MILLION)
  • TABLE 204. CHINA CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 205. CHINA CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 206. CHINA CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY INDUSTRIAL BIOCATALYSTS, 2018-2032 (USD MILLION)
  • TABLE 207. CHINA CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY THERAPEUTIC DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 208. CHINA CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 209. CHINA CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 210. CHINA CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY GENE LENGTH, 2018-2032 (USD MILLION)
  • TABLE 211. CHINA CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY SERVICE SPEED, 2018-2032 (USD MILLION)